Kelly Dopke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kelly Dopke has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
Kirsten N. Mansfield
Department of Orthopaedics, Penn State College of Medicine, Hershey, PA, USA
8 shared publications- Michael Aynardi
Penn State College of Medicine, Hershey, PA, USA
8 shared publications - Brandon J. Martinazzi
Rothman Orthopaedic Institute, Thomas Jefferson University, Philadelphia, PA, USA
6 shared publications Anna Ptasinski
5 shared publications- Gregory J. Kirchner
Department of Orthopaedics and Rehabilitation, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA
4 shared publications - Hannah Nam
Stanford University School of Medicine
4 shared publications
Latest Publications
- 16 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Orthopaedics
Concomitant Open Reduction Does Not Improve Outcomes in Patients Undergoing Osseous Reconstruction for Severe Hip Dysplasia Secondary to Cerebral Palsy: A Radiographic and Clinical Comparative Analysis
Background: Varus derotational osteotomy (VDRO) is frequently combined with pelvic osteotomy and open reduction to treat severe hip subluxation in children with cerebral palsy (CP). The purpose of this study was to compare outcomes of osseous hip reconstruction with and without open reduction in children with CP treated for severe hip subluxation or dislocation. Methods: This was a retrospective review of patients with CP and severe subluxation/dislocation [preoperative migration percentage (MP) ≥60%], who underwent VDRO with or without open reduction at 2 academic institutions between 2017 and 2023. Demographics, Gross Motor Function Classification System (GMFCS) level, key comorbidities, radiographic measurements, operative characteristics, and complications were collected. Statistical methods included descriptive analyses, the Mann-Whitney U test, a generalized linear mixed model, the Pearson χ 2 , and the Fisher exact test, with significance set at P P =0.17) and GMFCS distribution ( P =0.29) were similar. Group A had increased preoperative MP (86% vs. 77%, P =0.004), rate of overall comorbidity burden (100% vs. 79%, P =0.01), operative time (431.9 vs. 362.1 min, P P =0.03), rate of 90-day medical complications (47% vs. 22%, P =0.01), and rate of secondary surgery (17% vs. 1%, P =0.01) compared with group B. The number of pelvic osteotomies (1.1 vs. 1.3, P =0.23), rate of bilateral procedures (93% vs. 94%, P =1.0), rate of surgical complications (20% vs. 6%, P =0.07), final mean MP (21% vs. 15%, P =0.187), and the proportion of hips with a final MP ≥40% (14% vs. 9%, P =0.48) were comparable between groups. Conclusions: In patients with CP and severe hip subluxation, the addition of an open reduction is associated with longer operative time, increased blood loss, and higher complication/revision rates without demonstrable improvement in radiographic outcomes. These findings do not support the routine inclusion of open reduction as part of osseous hip reconstruction for severe CP-associated hip dysplasia. Level of Evidence: Level III.
- 16 September 2026
- Published by Wolters Kluwer Health in Journal of Pediatric Orthopaedics
Concomitant Open Reduction Does Not Improve Outcomes in Patients Undergoing Osseous Reconstruction for Severe Hip Dysplasia Secondary to Cerebral Palsy: A Radiographic and Clinical Comparative Analysis
Background: Varus derotational osteotomy (VDRO) is frequently combined with pelvic osteotomy and open reduction to treat severe hip subluxation in children with cerebral palsy (CP). The purpose of this study was to compare outcomes of osseous hip reconstruction with and without open reduction in children with CP treated for severe hip subluxation or dislocation. Methods: This was a retrospective review of patients with CP and severe subluxation/dislocation [preoperative migration percentage (MP) ≥60%], who underwent VDRO with or without open reduction at 2 academic institutions between 2017 and 2023. Demographics, Gross Motor Function Classification System (GMFCS) level, key comorbidities, radiographic measurements, operative characteristics, and complications were collected. Statistical methods included descriptive analyses, the Mann-Whitney U test, a generalized linear mixed model, the Pearson χ 2 , and the Fisher exact test, with significance set at P P =0.17) and GMFCS distribution ( P =0.29) were similar. Group A had increased preoperative MP (86% vs. 77%, P =0.004), rate of overall comorbidity burden (100% vs. 79%, P =0.01), operative time (431.9 vs. 362.1 min, P P =0.03), rate of 90-day medical complications (47% vs. 22%, P =0.01), and rate of secondary surgery (17% vs. 1%, P =0.01) compared with group B. The number of pelvic osteotomies (1.1 vs. 1.3, P =0.23), rate of bilateral procedures (93% vs. 94%, P =1.0), rate of surgical complications (20% vs. 6%, P =0.07), final mean MP (21% vs. 15%, P =0.187), and the proportion of hips with a final MP ≥40% (14% vs. 9%, P =0.48) were comparable between groups. Conclusions: In patients with CP and severe hip subluxation, the addition of an open reduction is associated with longer operative time, increased blood loss, and higher complication/revision rates without demonstrable improvement in radiographic outcomes. These findings do not support the routine inclusion of open reduction as part of osseous hip reconstruction for severe CP-associated hip dysplasia. Level of Evidence: Level III.
- 8 December 2025
- Published by Elsevier in Journal of Surgical Education
- Vol. 83 (2) , 103813
The Impact of Geographical Background on the Orthopedic Surgery Residency Match
- 8 December 2025
- Published by Elsevier in Journal of Surgical Education
- Vol. 83 (2) , 103813
The Impact of Geographical Background on the Orthopedic Surgery Residency Match
- Open Access
Charcot Neuroarthropathy: Current Concepts
In orthopaedics, there are exceptionally few disease entities that are as poorly understood and devoid of evidence-based guidelines as there are with Charcot Neuroarthropathy (CN) of the lower extremity. CN is associated with high morbidity and mortality rates, with its financial impact on the healthcare system being substantial. The disease is likely due to the combination of the previously described neurovascular and neurotraumatic theories. Thus, physicians should highly suspect CN in any diabetic patient with ulcers or apparent deformities. The recognition and further classification of CN can then help guide further management, which includes both nonoperative and operative approaches. The optimal timing for surgical intervention remains unknown; however, some authors have successfully operated during the acute phase of the disease. Caring for the Charcot patient requires a multidisciplinary approach, including infectious disease specialists, endocrinologists, wound care teams, social workers, and surgeons. As there are no current widely accepted evidence-based guidelines or algorithms used to manage patients, our topical review provides a framework for understanding, diagnosing, staging, and managing a patient with CN in addition to the author’s preferred treatment method and our approach to a patient diagnosed with CN.
Open AccessCharcot Neuroarthropathy: Current Concepts
In orthopaedics, there are exceptionally few disease entities that are as poorly understood and devoid of evidence-based guidelines as there are with Charcot Neuroarthropathy (CN) of the lower extremity. CN is associated with high morbidity and mortality rates, with its financial impact on the healthcare system being substantial. The disease is likely due to the combination of the previously described neurovascular and neurotraumatic theories. Thus, physicians should highly suspect CN in any diabetic patient with ulcers or apparent deformities. The recognition and further classification of CN can then help guide further management, which includes both nonoperative and operative approaches. The optimal timing for surgical intervention remains unknown; however, some authors have successfully operated during the acute phase of the disease. Caring for the Charcot patient requires a multidisciplinary approach, including infectious disease specialists, endocrinologists, wound care teams, social workers, and surgeons. As there are no current widely accepted evidence-based guidelines or algorithms used to manage patients, our topical review provides a framework for understanding, diagnosing, staging, and managing a patient with CN in addition to the author’s preferred treatment method and our approach to a patient diagnosed with CN.
- Open Access
- 20 April 2024
- Published by Wolters Kluwer Health in Regenerative Medicine Reports
- Vol. 1 (1) , 106-115
Impact of microtrauma on the erythropoietic receptor of neuropathic Schwann cell-deficient mice
Charcot neuropathic arthropathy is a degenerative disease commencing with vasculopathic peripheral neuropathy and progresses with repeated micro-trauma, leading to instability, collapse, and severe foot and ankle disruption. Prior work suggests that erythropoietin’s (EPO) anti-apoptotic and anti-inflammatory effects may be beneficial in functional recovery of traumatized limbs. Employing a validated murine model, we investigated if diet induced obese (DIO) EPO knockout mice experience accelerated neurodegenerative changes and if EPO administration blunts the degree of neurodegeneration compared with saline treatment and those lacking EPO receptors on Schwann cells. Sixteen wild-type (C57BL6) and 16 Schwann cell-deficient (MPZ Cre) mice were given a high fat diet, completed a 3-day EPO protocol, and began a 10-week treadmill regimen. Serum blood glucose levels were collected. None of the groups had elevated median blood glucoses. Sensory, radiographic, and histopathologic analysis demonstrated no evidence of Charcot neuropathic arthropathy. The neurodegenerative mouse model previously achieved was thus not replicated. While these genetically modified, knockout mice serve as suitable models for studying the impact of EPO on nerve crush injuries, the current study was unable to achieve neurodegeneration, as suggested by the lack of neuropathy. Furthermore, our DIO EPO group failed to demonstrate fundamental prerequisite phenotypic changes necessary in the establishment of a neurodegenerative mouse model. This model supports prior research by demonstrating that in the absence of DIO, repetitive traumatic insult alone does not induce neurodegenerative changes. Without these changes, researchers cannot appreciate differences between groups or observe interventions’ impact, such as EPO, on the development of neurodegeneration.
- 20 April 2024
- Published by Wolters Kluwer Health in Regenerative Medicine Reports
- Vol. 1 (1) , 106-115
Open AccessImpact of microtrauma on the erythropoietic receptor of neuropathic Schwann cell-deficient mice
Charcot neuropathic arthropathy is a degenerative disease commencing with vasculopathic peripheral neuropathy and progresses with repeated micro-trauma, leading to instability, collapse, and severe foot and ankle disruption. Prior work suggests that erythropoietin’s (EPO) anti-apoptotic and anti-inflammatory effects may be beneficial in functional recovery of traumatized limbs. Employing a validated murine model, we investigated if diet induced obese (DIO) EPO knockout mice experience accelerated neurodegenerative changes and if EPO administration blunts the degree of neurodegeneration compared with saline treatment and those lacking EPO receptors on Schwann cells. Sixteen wild-type (C57BL6) and 16 Schwann cell-deficient (MPZ Cre) mice were given a high fat diet, completed a 3-day EPO protocol, and began a 10-week treadmill regimen. Serum blood glucose levels were collected. None of the groups had elevated median blood glucoses. Sensory, radiographic, and histopathologic analysis demonstrated no evidence of Charcot neuropathic arthropathy. The neurodegenerative mouse model previously achieved was thus not replicated. While these genetically modified, knockout mice serve as suitable models for studying the impact of EPO on nerve crush injuries, the current study was unable to achieve neurodegeneration, as suggested by the lack of neuropathy. Furthermore, our DIO EPO group failed to demonstrate fundamental prerequisite phenotypic changes necessary in the establishment of a neurodegenerative mouse model. This model supports prior research by demonstrating that in the absence of DIO, repetitive traumatic insult alone does not induce neurodegenerative changes. Without these changes, researchers cannot appreciate differences between groups or observe interventions’ impact, such as EPO, on the development of neurodegeneration.
- Open Access
- 1 October 2023
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 8 (4)
Casting is a Cost-Effective Management Option in Appropriate Cases of Charcot Neuroarthropathy
Category: Diabetes; Midfoot/Forefoot Introduction/Purpose: Charcot Neuroarthropathy (CN) is a chronic and debilitating condition that impacts the nerves of the foot. The progression of CN may result in severe joint deformities, ulcers, and amputation in certain cases. Treatment options for CN include surgical interventions (e.g., arthrodesis, exostectomy, and amputation) and non-surgical interventions (e.g., casting). A cost analysis on the various treatment modalities can guide physicians to help their patients make informed decisions about their care. Here, we aim to characterize the total costs associated with the various treatments of CN, in addition to the physical therapy (PT) related costs. Methods: Following IRB approval, a sample of patients at a single institution diagnosed with CN of the lower extremity, who underwent exostectomy, arthrodesis, amputation, and/or casting were identified through patient records. Various demographics such as age, sex, and race were collected. Individuals were placed in their respective categories based on the first procedure they had performed. The groups were divided as follows: exostectomy, arthrodesis, major amputation, minor amputation, casting, and failed casting (the group that first received casting but later needed further intervention with other treatment modalities). Each procedure and PT appointment was counted toward the total cost. Descriptive statistics, t-tests, and one-way ANOVA were performed for statistical analysis. Results: Two-hundred and sixteen patients were identified; exostectomy (n = 81), arthrodesis (n = 47), major amputations (n = 10), minor amputations (n = 28), failed casting (n = 16), and casting (n = 34). The average age was 58 ± 12.1 years, and males accounted for 54% of the sample size with the various demographic information depicted in table 1. The effect of procedure type on total cost demonstrated a statistically significant difference between at least two groups (F-value = 18.53, p-value < 0.01), as demonstrated in figure 1. The total costs for casting were significantly lower than all other treatment modalities (p-value < 0.05). Furthermore, there was no statistical significance related to physical therapy costs among the groups (figure 2). Conclusion: Casting was demonstrated to be a more cost-effective management strategy for patients diagnosed with CN. However, it is important to note that this cost-related benefit is only apparent when CN patients are appropriately treated with casting, exemplified by the failed casting group. It is critical to utilize casting with appropriate patients in order to reduce the cost burden associated with these various management modalities. Early surgical intervention should still be strongly considered for patients who are not appropriate candidates for casting.
- 1 October 2023
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 8 (4)
Open AccessCasting is a Cost-Effective Management Option in Appropriate Cases of Charcot Neuroarthropathy
Category: Diabetes; Midfoot/Forefoot Introduction/Purpose: Charcot Neuroarthropathy (CN) is a chronic and debilitating condition that impacts the nerves of the foot. The progression of CN may result in severe joint deformities, ulcers, and amputation in certain cases. Treatment options for CN include surgical interventions (e.g., arthrodesis, exostectomy, and amputation) and non-surgical interventions (e.g., casting). A cost analysis on the various treatment modalities can guide physicians to help their patients make informed decisions about their care. Here, we aim to characterize the total costs associated with the various treatments of CN, in addition to the physical therapy (PT) related costs. Methods: Following IRB approval, a sample of patients at a single institution diagnosed with CN of the lower extremity, who underwent exostectomy, arthrodesis, amputation, and/or casting were identified through patient records. Various demographics such as age, sex, and race were collected. Individuals were placed in their respective categories based on the first procedure they had performed. The groups were divided as follows: exostectomy, arthrodesis, major amputation, minor amputation, casting, and failed casting (the group that first received casting but later needed further intervention with other treatment modalities). Each procedure and PT appointment was counted toward the total cost. Descriptive statistics, t-tests, and one-way ANOVA were performed for statistical analysis. Results: Two-hundred and sixteen patients were identified; exostectomy (n = 81), arthrodesis (n = 47), major amputations (n = 10), minor amputations (n = 28), failed casting (n = 16), and casting (n = 34). The average age was 58 ± 12.1 years, and males accounted for 54% of the sample size with the various demographic information depicted in table 1. The effect of procedure type on total cost demonstrated a statistically significant difference between at least two groups (F-value = 18.53, p-value < 0.01), as demonstrated in figure 1. The total costs for casting were significantly lower than all other treatment modalities (p-value < 0.05). Furthermore, there was no statistical significance related to physical therapy costs among the groups (figure 2). Conclusion: Casting was demonstrated to be a more cost-effective management strategy for patients diagnosed with CN. However, it is important to note that this cost-related benefit is only apparent when CN patients are appropriately treated with casting, exemplified by the failed casting group. It is critical to utilize casting with appropriate patients in order to reduce the cost burden associated with these various management modalities. Early surgical intervention should still be strongly considered for patients who are not appropriate candidates for casting.
- Open Access
- 1 October 2023
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 8 (4)
A Step in the Right Direction: Analyzing Differences in Demographics and Mortality in Operative Management of Charcot Neuroarthropathy
Category: Midfoot/Forefoot; Diabetes Introduction/Purpose: Charcot neuroarthropathy (CN) of the foot is a debilitating condition associated with diabetic neuropathy that involves progressive bone and joint destruction. Previous literature suggests the prevalence of CN is between 0.8%-8% in diabetic patients; however, CN diagnosis relies on skilled physician judgment, ultimately making management difficult. Physicians must account for the location, deformity, stage, and presence or absence of infection to appropriately treat CN. Correct diagnosis and treatment is essential to improving patients’ quality of life, but treatment varies with no definitive best-practice guidelines. Here, we provide demographic and all-cause mortality data for patients who underwent arthrodesis, exostectomy, minor amputations, and below-the-knee amputation (BKA), to evaluate the outcomes and characterize the populations managed with surgery for Charcot neuroarthropathy of the foot. Methods: Institutional review board approval was obtained. A database of all patients from 1/1/2000 to 1/31/2022 with CPT and ICD codes indicating a diagnosis of Charcot neuroarthropathy who underwent exostectomy, arthrodesis, and/or amputation was created from the electronic medical record. Demographic and mortality data was collected for the study sample, including date-of- birth, sex, race, and all-cause mortality. Procedure data was also collected, which included date, code, and description. Amputation patients were separated into major and minor; major include transtibial and trans-metatarsal, whereas minor include toe and metatarsal amputations. Descriptive statistics were conducted and single-factor ANOVA and Chi squared tests were used for analysis. Results: Of the 2,066 patients; 557 had arthrodesis, 493 had exostectomy, 681 had minor amputation, and 335 had major amputation. Average age was 58.17 ± 13.8 overall, and 54.8 ± 13.6, 55.0 ± 13.0, 61.6 ± 13.6, and 61.5 ± 13.4 years for arthrodesis, exostectomy, minor amputation, and major amputation, respectively. Females accounted for 56.6% of arthrodeses, 56.8% of exostectomies, 34.5% of minor amputations, and 28.4% of major amputations performed (p < 0.001). Patients were predominantly white in each group and overall, 2.1% were tobacco smokers. Mortality was 10.6%, 11.4%, 33.8%, and 31.9% in the arthrodesis, exostectomy, minor amputation, and major amputation groups, respectively (Figure 1). Conclusion: This is the first report of significant sample size (>2,000 patients) comparing both demographic and mortality between common surgical procedures for Charcot neuroarthropathy. Patients undergoing both minor and major amputations were more likely to be older and male compared to those undergoing less intensive operations. Most importantly, this data demonstrates that patients undergoing amputation have significantly worse mortality (33.8% and 31.9%) than those who undergo arthrodesis (10.6%) and exostectomy (11.4%). Future studies may include an analysis of cause-specific mortality for patients diagnosed with CN to evolve clinical and surgical management.
- 1 October 2023
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 8 (4)
Open AccessA Step in the Right Direction: Analyzing Differences in Demographics and Mortality in Operative Management of Charcot Neuroarthropathy
Category: Midfoot/Forefoot; Diabetes Introduction/Purpose: Charcot neuroarthropathy (CN) of the foot is a debilitating condition associated with diabetic neuropathy that involves progressive bone and joint destruction. Previous literature suggests the prevalence of CN is between 0.8%-8% in diabetic patients; however, CN diagnosis relies on skilled physician judgment, ultimately making management difficult. Physicians must account for the location, deformity, stage, and presence or absence of infection to appropriately treat CN. Correct diagnosis and treatment is essential to improving patients’ quality of life, but treatment varies with no definitive best-practice guidelines. Here, we provide demographic and all-cause mortality data for patients who underwent arthrodesis, exostectomy, minor amputations, and below-the-knee amputation (BKA), to evaluate the outcomes and characterize the populations managed with surgery for Charcot neuroarthropathy of the foot. Methods: Institutional review board approval was obtained. A database of all patients from 1/1/2000 to 1/31/2022 with CPT and ICD codes indicating a diagnosis of Charcot neuroarthropathy who underwent exostectomy, arthrodesis, and/or amputation was created from the electronic medical record. Demographic and mortality data was collected for the study sample, including date-of- birth, sex, race, and all-cause mortality. Procedure data was also collected, which included date, code, and description. Amputation patients were separated into major and minor; major include transtibial and trans-metatarsal, whereas minor include toe and metatarsal amputations. Descriptive statistics were conducted and single-factor ANOVA and Chi squared tests were used for analysis. Results: Of the 2,066 patients; 557 had arthrodesis, 493 had exostectomy, 681 had minor amputation, and 335 had major amputation. Average age was 58.17 ± 13.8 overall, and 54.8 ± 13.6, 55.0 ± 13.0, 61.6 ± 13.6, and 61.5 ± 13.4 years for arthrodesis, exostectomy, minor amputation, and major amputation, respectively. Females accounted for 56.6% of arthrodeses, 56.8% of exostectomies, 34.5% of minor amputations, and 28.4% of major amputations performed (p < 0.001). Patients were predominantly white in each group and overall, 2.1% were tobacco smokers. Mortality was 10.6%, 11.4%, 33.8%, and 31.9% in the arthrodesis, exostectomy, minor amputation, and major amputation groups, respectively (Figure 1). Conclusion: This is the first report of significant sample size (>2,000 patients) comparing both demographic and mortality between common surgical procedures for Charcot neuroarthropathy. Patients undergoing both minor and major amputations were more likely to be older and male compared to those undergoing less intensive operations. Most importantly, this data demonstrates that patients undergoing amputation have significantly worse mortality (33.8% and 31.9%) than those who undergo arthrodesis (10.6%) and exostectomy (11.4%). Future studies may include an analysis of cause-specific mortality for patients diagnosed with CN to evolve clinical and surgical management.
- Open Access
- 2 January 2023
- Published by Elsevier in Preventive Medicine Reports
- Vol. 31, 102109
Effects of COVID-19 pandemic on pediatric weight: A retrospective chart review
- 2 January 2023
- Published by Elsevier in Preventive Medicine Reports
- Vol. 31, 102109
Open AccessEffects of COVID-19 pandemic on pediatric weight: A retrospective chart review
- Open Access
- 1 January 2023
- Published by SAGE Publications in Child Neurology Open
- Vol. 10
Tacrolimus Induced Leukoencephalopathy and Stroke-Like Symptoms: Case Report
A 17-year-old female with sickle cell disease status post a recent stem cell transplant and on tacrolimus developed an acute expressive aphasia, dysphagia, and drooling. Brain MRI revealed diffuse restricted diffusion involving the bilateral corona radiata and areas of white matter in the right cerebral hemisphere most consistent with toxic leukoencephalopathy. Tacrolimus serum concentration was high at 19.3 ng/ml (ref 9-12 ng/ml) for which tacrolimus was discontinued. She was neurologically back at baseline 2 days later with the tacrolimus level improving to 8.2 ng/mL. Following discontinuation and the declining trend of her tacrolimus levels the patient returned to her neurologic baseline and was subsequently switched to mycophenolate mofetil for GVHD immunosuppression.
- 1 January 2023
- Published by SAGE Publications in Child Neurology Open
- Vol. 10
Open AccessTacrolimus Induced Leukoencephalopathy and Stroke-Like Symptoms: Case Report
A 17-year-old female with sickle cell disease status post a recent stem cell transplant and on tacrolimus developed an acute expressive aphasia, dysphagia, and drooling. Brain MRI revealed diffuse restricted diffusion involving the bilateral corona radiata and areas of white matter in the right cerebral hemisphere most consistent with toxic leukoencephalopathy. Tacrolimus serum concentration was high at 19.3 ng/ml (ref 9-12 ng/ml) for which tacrolimus was discontinued. She was neurologically back at baseline 2 days later with the tacrolimus level improving to 8.2 ng/mL. Following discontinuation and the declining trend of her tacrolimus levels the patient returned to her neurologic baseline and was subsequently switched to mycophenolate mofetil for GVHD immunosuppression.
- Open Access
- 15 November 2022
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 7 (4)
Can Sociodemographic Factors be Used to Help Predict Outcomes in Charcot Neuroarthropathy?
Category: Diabetes; Other Introduction/Purpose: The diabetic Charcot foot, or Charcot neuroarthropathy, is a devastating condition that arises secondary to longstanding diabetes, peripheral neuropathy, and trauma. One of the many challenges associated with the Charcot patient is the lack of data exploring factors that may predict long-term outcomes. Therefore, the purpose of this study was to evaluate how certain sociodemographic factors may influence mortality and the need to undergo lower extremity amputation in patients with Charcot. Methods: Following institutional board approval, all patients from 2015-2021 with a diagnosis of Charcot Foot were queried using hospital electronic medical records. Demographics collected included sex, age, race, and insurance coverage. Outcomes recorded were the need to undergo major amputation and mortality rate. Statistical analysis was then run to determine if sex, age, race, and insurance coverage was associated with increased risk of needing a major amputation or death. Results: From 2015-2021, 80 Charcot patients with a mean age of 60 (Range, 84-32) were identified. Of these patients, 58 were male, 26 were female, 71 were white, 3 were African American, and 6 were identified as other. In our cohort, 47 patients had government funded insurance and 33 had private insurance. Amputation occurred in 22 patients and death in 15. Government funded insurance (RR: 9.8, 95% CI:1.4-71.1, P = 0.0236) and age over 65 was associated with an increased risk of death (RR: 2.5, 95% CI: 1.02 to 6.17; P = 0.044). No statistically significant increased risk of death or amputation was found in white, African American, male, or female patients. Government insurance was also not associated with an increased risk for amputation (Table 1). Conclusion: Charcot Neuroarthropathy is associated with high rates of morbidity and mortality. In our cohort, there was an increased risk of mortality in patients with government funded insurance and patients over the age of 65. Further investigation exploring the role of sociodemographic factors is warranted.
- 15 November 2022
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 7 (4)
Open AccessCan Sociodemographic Factors be Used to Help Predict Outcomes in Charcot Neuroarthropathy?
Category: Diabetes; Other Introduction/Purpose: The diabetic Charcot foot, or Charcot neuroarthropathy, is a devastating condition that arises secondary to longstanding diabetes, peripheral neuropathy, and trauma. One of the many challenges associated with the Charcot patient is the lack of data exploring factors that may predict long-term outcomes. Therefore, the purpose of this study was to evaluate how certain sociodemographic factors may influence mortality and the need to undergo lower extremity amputation in patients with Charcot. Methods: Following institutional board approval, all patients from 2015-2021 with a diagnosis of Charcot Foot were queried using hospital electronic medical records. Demographics collected included sex, age, race, and insurance coverage. Outcomes recorded were the need to undergo major amputation and mortality rate. Statistical analysis was then run to determine if sex, age, race, and insurance coverage was associated with increased risk of needing a major amputation or death. Results: From 2015-2021, 80 Charcot patients with a mean age of 60 (Range, 84-32) were identified. Of these patients, 58 were male, 26 were female, 71 were white, 3 were African American, and 6 were identified as other. In our cohort, 47 patients had government funded insurance and 33 had private insurance. Amputation occurred in 22 patients and death in 15. Government funded insurance (RR: 9.8, 95% CI:1.4-71.1, P = 0.0236) and age over 65 was associated with an increased risk of death (RR: 2.5, 95% CI: 1.02 to 6.17; P = 0.044). No statistically significant increased risk of death or amputation was found in white, African American, male, or female patients. Government insurance was also not associated with an increased risk for amputation (Table 1). Conclusion: Charcot Neuroarthropathy is associated with high rates of morbidity and mortality. In our cohort, there was an increased risk of mortality in patients with government funded insurance and patients over the age of 65. Further investigation exploring the role of sociodemographic factors is warranted.
- Open Access
- 15 November 2022
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 7 (4)
Few Randomized Controlled Trials in Foot and Ankle Orthopaedics Include Sociodemographic Patient Data
Category: Other Introduction/Purpose: Social determinants of health play a major role in patient care. Factors such as race, education, and income have all been shown to impact patient outcomes in orthopaedic surgery. While retrospective studies are often limited by data availability, prospective randomized controlled trials (RCTs) are able to select their own patient demographics to be included in their analyses. However, the representation of sociodemographic data within RCTs regarding foot and ankle surgery is undefined. Therefore, the purpose of this study was to determine the incidence of sociodemographic data being reported in contemporary foot and ankle RCTs. Methods: RCTs within the PubMed database from 2016-2021 were searched using the search term 'Foot and Ankle Surgery.' Each article's journal of publication, year of publication, and outcome of interest were recorded. Articles were separated into the following outcomes of interest: Infection prevention, pain control, surgical outcomes, and non-operative outcomes. The full text of each article was reviewed to identify sociodemographic variables within the results or tables versus any part of the article (i.e., results or otherwise). Sociodemographic variables collected were race, ethnicity, insurance status, income, work status, and education. We then used the Fisher exact test to compare inclusion of sociodemographic data by journal, year, and outcome type. Results: A total of 34 studies across 15 different journals were included in our analysis. Of the 34 studies, 12 were grouped into operative outcomes, 11 into pain control, 7 into non-operative outcomes, and 4 into infection prevention. Race was reported in the results in 2 studies (5.9%), ethnicity in 1 (2.9%), insurance status in 0, income in 0, work status in 1 (2.9%) and education in 1 (2.9%). In any section other than the results, race was reported in 3 studies (8.8%), ethnicity in 1 (2.9%), insurance status in 3 (8.8%), income in 4 (11.8%), work status in 2 (5.9%), and education in 1 (2.9%). There was no difference found when comparing sociodemographic data to journal (p=0.127), year of publication (p=0.495), or outcome studies (p=0.439). Conclusion: The overall rate of sociodemographic data reported in foot and ankle RCTs is low. There was no difference in the reporting of sociodemographic data between journal, year of publication, or outcome of study.
- 15 November 2022
- Published by SAGE Publications in Foot & Ankle Orthopaedics
- Vol. 7 (4)
Open AccessFew Randomized Controlled Trials in Foot and Ankle Orthopaedics Include Sociodemographic Patient Data
Category: Other Introduction/Purpose: Social determinants of health play a major role in patient care. Factors such as race, education, and income have all been shown to impact patient outcomes in orthopaedic surgery. While retrospective studies are often limited by data availability, prospective randomized controlled trials (RCTs) are able to select their own patient demographics to be included in their analyses. However, the representation of sociodemographic data within RCTs regarding foot and ankle surgery is undefined. Therefore, the purpose of this study was to determine the incidence of sociodemographic data being reported in contemporary foot and ankle RCTs. Methods: RCTs within the PubMed database from 2016-2021 were searched using the search term 'Foot and Ankle Surgery.' Each article's journal of publication, year of publication, and outcome of interest were recorded. Articles were separated into the following outcomes of interest: Infection prevention, pain control, surgical outcomes, and non-operative outcomes. The full text of each article was reviewed to identify sociodemographic variables within the results or tables versus any part of the article (i.e., results or otherwise). Sociodemographic variables collected were race, ethnicity, insurance status, income, work status, and education. We then used the Fisher exact test to compare inclusion of sociodemographic data by journal, year, and outcome type. Results: A total of 34 studies across 15 different journals were included in our analysis. Of the 34 studies, 12 were grouped into operative outcomes, 11 into pain control, 7 into non-operative outcomes, and 4 into infection prevention. Race was reported in the results in 2 studies (5.9%), ethnicity in 1 (2.9%), insurance status in 0, income in 0, work status in 1 (2.9%) and education in 1 (2.9%). In any section other than the results, race was reported in 3 studies (8.8%), ethnicity in 1 (2.9%), insurance status in 3 (8.8%), income in 4 (11.8%), work status in 2 (5.9%), and education in 1 (2.9%). There was no difference found when comparing sociodemographic data to journal (p=0.127), year of publication (p=0.495), or outcome studies (p=0.439). Conclusion: The overall rate of sociodemographic data reported in foot and ankle RCTs is low. There was no difference in the reporting of sociodemographic data between journal, year of publication, or outcome of study.